Kanion Pharmaceutical(SH:600557) Sou Hu Cai Jing·2025-08-22 21:36Group 1 - The article reports that Jiangsu Zhongxin Pharmaceutical Co., Ltd. has applied for a "Type III meeting" with the CDE, which is currently in processing status [1] - Type III meetings are typically held within 75 days after the application and focus on significant issues at critical stages of drug development [1] - Jiangsu Zhongxin Pharmaceutical was established in 2011 and is primarily engaged in technology promotion and application services, with a registered and paid-in capital of 95 million RMB [1] Group 2 - The company has made one external investment, participated in one bidding project, and holds 8 trademark registrations and 13 patents [1] - Jiangsu Zhongxin Pharmaceutical has 40 administrative licenses [1] - The company is wholly owned by Jiangsu Kangyuan Pharmaceutical Co., Ltd. [1]